October 15, 2019 09:50 AM EDTUpdated 10:38 AM
News Briefing

Check­mate Phar­ma­ceu­ti­cals brings two new ex­ecs on board; Take­da sheds 30 drugs, gains $200M in Aci­no deal

Kathy Wong

Editor

→ Amid a $22 mil­lion fi­nanc­ing round led by Decheng Cap­i­tal last year, Check­mate Phar­ma­ceu­ti­cals CEO Art Krieg an­nounced that he was turn­ing in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times